Masimo (MASI)

Executive Summary

Masimo is a global leader in non-invasive patient monitoring, best known for its Signal Extraction Technology (SET®) pulse oximetry. The company has expanded from hospital monitoring into home care and consumer health with products like the Masimo W1 watch and MightySat fingertip pulse oximeter. Despite facing competition from traditional players and new entrants, Masimo's technology remains widely adopted in critical care settings, providing a strong recurring revenue stream from consumable sensors. Recent legal disputes with Apple over patent infringement and ongoing FDA clearance processes for next-generation devices are key factors that could shape the company's near-term performance. Financially, Masimo has shown resilience with steady revenue growth driven by sensor sales and international expansion, though hospital capital spending headwinds have tempered new system placements.

Upcoming Catalysts (preview)

• Q2 2026Resolution or Escalation of Apple Patent Litigation60% success
• Q3 2026FDA Clearance of Next-Generation Pulse Oximetry Sensor75% success
• Q4 2026Launch of Masimo W2 Consumer Health Watch50% success